Anhui, July 16, 2025 — Leman Biotech Co., Ltd., a clinical-stage biotechnology company focused on metabolic immunotherapies, announced the initiation of an Investigator-Initiated Trial (IIT) for its novel Metabolically Armored BCMA CAR-T (Meta10-BCMA CAR-T) cell therapy.The trial will be conducted at the First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) and aims to evaluate the safety and efficacy of Meta 10-BCMA CAR-T in patients with relapsed or refractory plasma cell neoplasms.

Anhui, July 11, 2025 — Leman Biotech Co., Ltd., a clinical-stage biotechnology company specializing in metabolic immunotherapies, announced the official initiation of an Investigator-Initiated Trial (IIT) to evaluate Meta10-TILs, its novel metabolically armored tumor-Infiltrating Lymphocyte therapy, for the treatment of advanced solid tumors. 
 

Hangzhou, June 12, 2025 - Leman Biotech Co., Ltd. ("Leman Biotech"), a clinical-stage biotechnology company focused on the research, development, production, and commercialization of innovative metabolic immunotherapies, announced a significant clinical progress made in its investigator-initiated trial (IIT) for metabolically armed CD19 CAR-T cell therapy (Meta10-19 injection). The first enrolled systemic lupus erythematosus (SLE) patient achieved "medication-free DORIS remission" (complete remission without ongoing treatment) after receiving a single infusion of Meta10-19 injection at a dose of only 1‰ (one-thousandth) of the standard commercial CAR-T dose (2×10⁶ CAR-T cell/kg). The patient discontinued all SLE-related medications following clinical assessment.

Anhui, April 26, 2025 - Leman Biotech Co., Ltd. ("Leman Biotech"), a clinical-stage biotechnology company focused on the research, development, production, and commercialization of innovative metabolic immunotherapies, recently announced the successful treatment of the first patient enrolled in its investigator-initiated clinical trial (IIT) for relapsed/refractory chronic lymphocytic leukemia (R/R CLL). The patient, treated with an extremely low dose, was assessed to have achieved complete remission (CR) and was discharged successfully.

Lausanne, January 8, 2025 – Leman Biotech Co., Ltd. ("Leman Biotech"), a clinical-stage biotechnology company focused on the research, development, production, and commercialization of innovative metabolic immunotherapies, is thrilled to announce that its co-founder, Prof. Li Tang, has been named one of the two recipients of the Friedrich Miescher Award 2025!

Hangzhou, November 29, 2024 – The First Affiliated Hospital of Zhejiang University School of Medicine recently held the clinical launch meeting for an expansion of the investigator-initiated clinical trial (IIT) to include relapsed or refractory indolent B-cell non-Hodgkin lymphoma (r/r B-iNHL) as a new indication for Leman Biotech's metabolically armed CD19 CAR-T therapy, Meta10-19 therapy. The clinical protocol focuses on preparing allogeneic CAR-T cells using fully matched or partially matched donor lymphocytes, aiming to provide more patients with timely and high-quality CAR-T therapy.

Hangzhou, November 28, 2024 - the First Affiliated Hospital of Zhejiang University School of Medicine successfully held the clinical launch meeting to include moderate to severe active systemic lupus erythematosus (SLE) into the investigator-initiated clinical trial (IIT) for the metabolically armed CD19 CAR-T cells (Meta10-19 Injection).

Zhongshan, November 21, 2024 – Leman Biotech Co., Ltd. (hereinafter referred to as "Leman Biotech"), a clinical-stage biotechnology company dedicated to the research, development, production, and commercialization of innovative metabolic immunotherapies, is pleased to announce the official commencement of its operations at Zhongshan Life Science Park. This milestone marks a pivotal advancement in the development of state-of-the-art, automated, and fully enclosed Chemistry, Manufacturing, and Controls (CMC) processes designed for the production of ultra-low dose Chimeric Antigen Receptor T-cell (CAR-T) therapies.